ArticleMolecular therapy. Oncology2025
Installation of dominant-negative mutations in
Bryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, Joseph G Skeate, Ethan M Niemeyer, Beau R Webber, Branden S Moriarity
Abstract read
In one paragraphArticle in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors.
Bryce J WickDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Mitchell G KluesnerMolecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA.
Nicholas J SlipekDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Ethan M NiemeyerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Beau R WebberDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MProject 4:Targeting M2-like Macrophages and MDSC with Myelolytic-VirotherapyU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CAIRO, MITCHELL S., CRIPE, TIMOTHY P · 2019 to 2023
$12.1MTRAINING IN HEMOGLOBIN &CELL MEMBRANE RESEARCHT32HL007062 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller, Gregory M Vercellotti · 1985 to 2026
$10.3MProject 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2021 to 2025
$9.4MTECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI David J. Odde · 2022 to 2026
$8.2MSCGE Disease Models Studies Supplement: Evaluation of prime editing for the amelioration of alpha-1-antitrypsin deficiency in murine and porcine models.U24OD026641 · OD · RECOMBINETICS, INC. · PI CARLSON, DANIEL FRED · 2018 to 2022
$4.1MActivated NK CAR Cells to Cure HIVR01AI161017 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S, SKINNER, PAMELA J · 2021 to 2025
$3.8MDeconvoluting the Ewing sarcoma genetic program using ancestry-informed human iPSC modelingR37CA276345 · NCI · UNIVERSITY OF MINNESOTA · PI Beau Richard Webber · 2023 to 2026
$2.2MEngineered B Cells as a Universal Platform for the Treatment of EnzymopathiesR01AI146009 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2020 to 2024
$1.9MHuman iPSC-Derived Chimeric Antigen Receptor Macrophages to Modulate Inflammation and Combat Tau-Induced PathologyR61AG090358 · NIA · UNIVERSITY OF MINNESOTA · PI Jonathan N Sachs, Beau Richard Webber · 2025 to 2026
$1.5MMultiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426kNCI NIH HHS F30 CA305905NCI NIH HHS P01 CA254849NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA136393NCI NIH HHS R21 CA237789NCI NIH HHS R37 CA276345NCI NIH HHS U54 CA232561NCI NIH HHS U54 CA268069NHLBI NIH HHS T32 HL007062NIAID NIH HHS R01 AI146009NIAID NIH HHS R01 AI161017NIAID NIH HHS R21 AI163731NIA NIH HHS R61 AG090358NIH HHS U24 OD026641
6 · The paper itselfAbstract
Adoptive cell transfer (ACT) of engineered T cells is effective against B cell malignancies but has faltered against solid tumors due to the immunosuppressive tumor microenvironment (TME). FAS ligand (FASL) and transforming growth factor β (TGF-β) are key mediators of T cell dysfunction in the TME and overexpressing dominant negative (dn) forms of their receptors in T cells increases anti-tumor efficacy in solid tumor models. However, an approach that directly targets the endogenous genes would be more amenable to multiplex editing and reduce competition with WT alleles. Here, we employ base editing (BE) in primary human T cells to install naturally occurring dominant negative
Indexed as
base editorscancer immunotherapyCAR-Tdominant-negative mutationsMT: Regular IssueT cells
Identifiers
PMID41141367
PMCPMC12547302
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390